Azobenzenes

Medchemexpress LLC 4-N,6-N-bis[(4-fluoro-3-methylphenyl)methyl]pyrimidine-4,6-dicarboxamide | 544678-85-5 | MFCD09878513 | 99.2% | 410.42 g/mol | C22H20F2N4O2 | 5MG

DB04760 is a potent, highly selective, non-zinc-chelating inhibitor of matrix metalloproteinase-13 (MMP-13) with a reported IC50 of 8 nM. In preclinical studies it reduced paclitaxel-induced neurotoxicity and exhibited anticancer activity. The compound is supplied for research use in multiple solid and solution formats and is provided with high purity.

• Potent MMP-13 inhibitor (IC50 = 8 nM).
• Non-zinc-chelating mechanism reduces off-target zinc interaction risk.
• Shown to reduce paclitaxel-induced neurotoxicity in studies.
• Exhibits anticancer activity in reported preclinical work.
• High purity (≈99.2%) with molecular weight 410.42 and formula C22H20F2N4O2.
• Available in solid and DMSO solution formats for research applications.

Medchemexpress LLC 4-N,6-N-bis[(4-fluoro-3-methylphenyl)methyl]pyrimidine-4,6-dicarboxamide | 544678-85-5 | MFCD09878513 | 99.2% | 410.42 g/mol | C22H20F2N4O2 | 1MG

DB04760 is a potent, highly selective, non-zinc-chelating inhibitor of matrix metalloproteinase-13 (MMP-13) with a reported biochemical IC50 of 8 nM. Preclinical studies show the compound reduces paclitaxel-induced neurotoxicity and exhibits anticancer activity. The material is supplied as a light yellow to yellow solid with high purity and recommended storage conditions for powder and solution forms.

Medchemexpress LLC DB04760 | 544678-85-5 | 99.2% | 410.42 g·mol⁻¹ | C22H20F2N4O2 | 50MG

DB04760 is a potent, highly selective, non-zinc-chelating MMP-13 inhibitor (IC50 = 8 nM) used as a research reagent in preclinical studies. It has been reported to reduce paclitaxel-induced neurotoxicity and to exhibit anticancer activity. The compound has formula C22H20F2N4O2, molecular weight 410.42 g·mol⁻¹, and is supplied in solid and solution forms with high purity suitable for biological assays.

• Potent MMP-13 inhibition with IC50 = 8 nM.
• Non-zinc-chelating mechanism for selective target studies.
• Shown to reduce paclitaxel-induced neurotoxicity in models.
• Reported anticancer activity in preclinical research.
• Available as solid and as 10 mM solution in DMSO for assay flexibility.
• High purity (~99%) appropriate for biological testing.

Medchemexpress LLC DB04760 (compound 4) | 544678-85-5 | MFCD09878513 | 99.2% | 410.42 g/mol | C22H20F2N4O2 | 10MG

DB04760 is a small-molecule MMP-13 inhibitor (compound 4) reported as a potent, highly selective, non-zinc-chelating inhibitor with an IC50 of 8 nM. It has been used in studies showing reduction of paclitaxel-induced neurotoxicity and anticancer activity, and is supplied for research use with defined purity and solubility characteristics.

• Potent MMP-13 inhibitor with IC50 = 8 nM.
• Highly selective non-zinc-chelating mechanism.
• Molecular formula C22H20F2N4O2, molecular weight 410.42 g/mol.
• CAS number 544678-85-5.
• Purity 99.2%.
• Soluble in DMSO at ≥100 mg/mL; in vivo formulation: 10% DMSO then 90% corn oil.
• Reported to reduce paclitaxel neurotoxicity and exhibit anticancer activity.
• Available in multiple small-scale pack sizes for research use.